(Q33560136)

28 July 2017

1 reference

title

Systemic therapy in breast cancer: efficacy and cost utility (English)

1 reference

28 July 2017

1 reference

2

Lønning PE

1 reference

28 July 2017

Corry JF

1

1 reference

28 July 2017

1 March 1994

1 reference

28 July 2017

1 reference

28 July 2017

5

1 reference

28 July 2017

3

1 reference

28 July 2017

198-212

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199405030-00004

28 July 2017

0 references

cites work

A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report

1 reference

12 December 2020

Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial

1 reference

12 December 2020

A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma

1 reference

12 December 2020

Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases

1 reference

12 December 2020

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

1 reference

12 December 2020

Chemotherapy of breast cancer: current views and results.

1 reference

12 December 2020

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model

1 reference

12 December 2020

Massive estrogen administration in premenopausal women with metastatic breast cancer

1 reference

12 December 2020

Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.

1 reference

12 December 2020

Tamoxifen (antiestrogen) therapy in advanced breast cancer

1 reference

12 December 2020

Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values

1 reference

12 December 2020

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

1 reference

12 December 2020

Primary radiation therapy for locally advanced breast cancer

1 reference

12 December 2020

HRT: an analysis of benefits, risks and costs

1 reference

12 December 2020

Treatment of breast carcinoma with aminoglutethimide.

1 reference

12 December 2020

CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY

1 reference

12 December 2020

Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin

1 reference

12 December 2020

Prognostic factors in metastatic breast cancer treated with combination chemotherapy

1 reference

12 December 2020

Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery

1 reference

12 December 2020

Medical and surgical adrenalectomy in patients with advanced breast carcinoma

1 reference

12 December 2020

Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients

1 reference

12 December 2020

Endocrine treatment of breast cancer in women

1 reference

12 December 2020

Breast cancer surveillance--a cost-effective strategy

1 reference

12 December 2020

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results

1 reference

12 December 2020

Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy

1 reference

12 December 2020

The cost of breast cancer recurrences

1 reference

12 December 2020

Quality of life assessment for cost/utility studies in cancer

1 reference

12 December 2020

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

12 December 2020

Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.

1 reference

12 December 2020

Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension

1 reference

12 December 2020

Selection of therapy for stage III breast cancer

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Advanced breast cancer: use of resources and cost implications

1 reference

12 December 2020

Mechanism of action of adjuvant chemotherapy in early breast cancer

1 reference

12 December 2020

Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma

1 reference

12 December 2020

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

12 December 2020

The use of prednisolone in the treatment of disseminated breast carcinoma

1 reference

12 December 2020

Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update

1 reference

12 December 2020

Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

1 reference

12 December 2020

Does chemotherapy improve survival in advanced breast cancer? A statistical overview

1 reference

12 December 2020

Long-term survival of patients with breast cancer: a study of the curability of the disease

1 reference

12 December 2020

Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer

1 reference

12 December 2020

Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer

1 reference

12 December 2020

Discounting in cost-effectiveness analysis of healthcare programmes

1 reference

12 December 2020

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial

1 reference

12 December 2020

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

12 December 2020

Prognostic factors in metastatic breast cancer

1 reference

12 December 2020

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

12 December 2020

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

12 December 2020

Quality adjusted survival analysis

1 reference

12 December 2020

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

12 December 2020

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

1 reference

12 December 2020

Cost-effectiveness analysis of end-stage renal disease treatments

1 reference

12 December 2020

Screening for hypertension

1 reference

12 December 2020

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

12 December 2020

The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review

1 reference

12 December 2020

A ten-year study of 5-flurouracil in disseminated breast cancer with clinical results and survival times

1 reference

12 December 2020

Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.

1 reference

12 December 2020

An evaluation of routine follow-up for detection of breast cancer recurrences

1 reference

12 December 2020

Principles of pharmacoeconomic analysis of drug therapy

1 reference

12 December 2020

Time preferences for health gains: an empirical investigation

1 reference

12 December 2020

Steroid receptors in human breast cancer

1 reference

12 December 2020

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women

1 reference

12 December 2020

The economic value of life: linking theory to practice

1 reference

12 December 2020

Symptomatology as an indicator of recurrent or metastatic breast cancer

1 reference

12 December 2020

Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer

1 reference

12 December 2020

Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

12 December 2020

Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer

1 reference

12 December 2020

Assessment of response to therapy in advanced breast cancer

1 reference

12 December 2020

Advanced breast cancer and its prevention by screening

1 reference

12 December 2020

[Hypophysectomy in man.]

1 reference

12 December 2020

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

12 December 2020

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

12 December 2020

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse

1 reference

12 December 2020

Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience

1 reference

12 December 2020

Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy

1 reference

12 December 2020

A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.

1 reference

12 December 2020

Cortisone treatment of metastatic breast cancer

1 reference

12 December 2020

Increasing incidence and constant mortality rates of breast cancer: time trends in Stockholm County 1961-1973

1 reference

12 December 2020

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

12 December 2020

Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer

1 reference

12 December 2020

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Does the breast cancer dollar make sense?

1 reference

12 December 2020

Clinical results with megestrol acetate in patients with advanced carcinoma of the breast

1 reference

12 December 2020

Improved survival of patients with metastatic breast cancer receiving combination chemotherapy

1 reference

12 December 2020

Prognostic value of estrogen receptors in primary breast cancer

1 reference

12 December 2020

Financial considerations in the use of adjuvant chemotherapy

1 reference

12 December 2020

The utility of different health states as perceived by the general public

1 reference

12 December 2020

Inhibition of human mammary and prostatic cancers by adrenalectomy

1 reference

12 December 2020

Cultured mammary carcinoma cells contain gonadotropin-releasing hormone-like immunoreactivity, GnRH binding sites and chorionic gonadotropin

1 reference

12 December 2020

Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer

1 reference

12 December 2020

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

1 reference

12 December 2020

Ovarian function and adjuvant chemotherapy for early breast cancer

1 reference

12 December 2020

10.2165/00019053-199405030-00004

Identifiers

DOI

1 reference

PubMed ID

10146895

Dimensions Publication ID

28 July 2017

0 references

1 reference

PubMed ID

10146895